MicroPort Medical (00853.HK): Subsidiary MicroPort Endovascular (688016.SH) Forecasts Jan-Sep 2023 Net Profit of RMB 385–400 Million, Up 28%–33% Year-on-Year

Intelligent Finance APP News, MicroPort (00853) announced that Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec (688016.SH)) expects its operating revenue for January to September 2023 to be between RMB 864 million and RMB 897 million, representing a year-on-year increase of 30% to 35%. The net profit attributable to shareholders of the listed company is expected to be approximately RMB 385 million to RMB 400 million, representing a year-on-year increase of 28% to 33%.

The announcement stated that from January to September 2023, the company's business scale continued to expand, with overseas sales growing beyond expectations, driving a rapid year-on-year increase in the company’s revenue. The company’s new products achieved relatively fast growth in both the number of hospitals adopting them and the volume of terminal implants. The company will continue to enhance its competitiveness in the aortic and peripheral vascular intervention markets and maintain a rapid growth trend.